Key result
Meditation interventions provided very little information on cardiovascular clinical endpoints, with substantial heterogeneity limiting the certainty of findings for blood pressure and psychological outcomes.
Why the study?
Stress is a cardiovascular disease risk factor, and meditation is increasingly popular, but its effectiveness for primary and secondary cardiovascular prevention remained to be determined.
Does meditation reduce cardiovascular events, blood pressure, and psychological distress in adults at high risk of or with established cardiovascular disease?
Systematic Review (n=6,971)
Does meditation reduce cardiovascular events, blood pressure, and psychological distress in adults at high risk of or with established cardiovascular disease?
Meditation may reduce blood pressure and psychological stress in patients at risk for or with cardiovascular disease, but evidence is limited by small study sizes, high heterogeneity, and a lack of data on hard clinical endpoints.
Answers are grounded in this paper and cite their sources.
Insufficient evidence to recommend meditation in CVD; leaves open effects on clinical endpoints and BP while suggesting anxiety benefits.
BACKGROUND: Interventions incorporating meditation to address stress, anxiety, and depression, and improve self-management, are becoming popular for many health conditions. Stress is a risk factor for cardiovascular disease (CVD) and clusters with other modifiable behavioural risk factors, such as smoking. Meditation may therefore be a useful CVD prevention strategy. OBJECTIVES: To determine the effectiveness of meditation, primarily mindfulness-based interventions (MBIs) and transcendental meditation (TM), for the primary and secondary prevention of CVD. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, three other databases, and two trials registers on 14 November 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of 12 weeks or more in adults at high risk of CVD and those with established CVD. We explored four comparisons: MBIs versus active comparators (alternative interventions); MBIs versus non-active comparators (no intervention, wait list, usual care); TM versus active comparators; TM versus non-active comparators. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were CVD clinical events (e.g. cardiovascular mortality), blood pressure, measures of psychological distress and well-being, and adverse events. Secondary outcomes included other CVD risk factors (e.g. blood lipid levels), quality of life, and coping abilities. We used GRADE to assess the certainty of evidence. MAIN RESULTS: = 18%; very low-certainty evidence). One trial (112 participants) reported anxiety and depression and found reductions in both (anxiety SMD -0.71 units, 95% CI -1.09 to -0.32; depression SMD -0.48 units, 95% CI -0.86 to -0.11; low-certainty evidence). None of the trials reported CVD clinical events, adverse events, or smoking rates. AUTHORS' CONCLUSIONS: Despite the large number of studies included in the review, heterogeneity was substantial for many of the outcomes, which reduced the certainty of our findings. We attempted to address this by presenting four main comparisons of MBIs or TM versus active or inactive comparators, and by subgroup analyses according to primary or secondary prevention, where there were sufficient studies. The majority of studies were small and there was unclear risk of bias for most domains. Overall, we found very little information on the effects of meditation on CVD clinical endpoints, and limited information on blood pressure and psychological outcomes, for people at risk of or with established CVD. This is a very active area of research as shown by the large number of ongoing studies, with some having been completed at the time of writing this review. The status of all ongoing studies will be formally assessed and incorporated in further updates.
No takes yet. Share an insight, caveat, or question.
Rees et al. (2024) conducted a systematic review in Cardiovascular disease (primary and secondary prevention) (n=6,971). Meditation (mindfulness-based interventions and transcendental meditation) vs. Active or non-active comparators was evaluated on Clinical CVD events (MBIs vs non-active comparators) (RR 0.94, 95% CI 0.37 to 2.42). Meditation interventions provided very little information on cardiovascular clinical endpoints, with substantial heterogeneity limiting the certainty of findings for blood pressure and psychological outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: